Director/PDMR Shareholding

RNS Number : 8147F
GlaxoSmithKline PLC
23 March 2022
 

GlaxoSmithKline plc   (the ' Company ')

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Sir Jonathan Symonds

b)

Position/status

Non-Executive Chair

 

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2022 to 31 March 2022.

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£15.90

2,751.797

 

 

 

 

 

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

 

e)

Date of the transaction

2022-03-23

f)

Place of the transaction

 

N/A

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr Charles Bancroft

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

 

b)

Nature of the transaction

Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2022 to 31 March 2022.

 

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

$42.28

1,394.862

 

 

 

 

 

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

 

e)

Date of the transaction

2022-03-23

f)

Place of the transaction

 

N/A

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr Vindi Banga

b)

Position/status

Senior Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2022 to 31 March 2022.

 

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£15.90

570.015

 

 

 

 

 

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

 

e)

Date of the transaction

2022-03-23

f)

Place of the transaction

 

N/A

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Anne Beal

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

 

b)

Nature of the transaction

Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2022 to 31 March 2022.

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

$ 42.28

189.303

 

 

 

 

 

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

 

e)

Date of the transaction

2022-03-23

f)

Place of the transaction

 

N/A

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dame Vivienne Cox

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2022 to 31 March 2022.

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£15.90

530.704

 

 

 

 

 

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

 

e)

Date of the transaction

2022-03-23

f)

Place of the transaction

 

N/A

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Hal Dietz

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

 

b)

Nature of the transaction

Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2022 to 31 March 2022.

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

$ 42.28

328.789

 

 

 

 

 

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

 

e)

Date of the transaction

2022-03-23

f)

Place of the transaction

 

N/A

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms Lynn Elsenhans

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

 

b)

Nature of the transaction

Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2022 to 31 March 2022.

 

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

$42.28

269.009

 

 

 

 

 

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

 

e)

Date of the transaction

2022-03-23

f)

Place of the transaction

 

N/A

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Laurie Glimcher

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

 

b)

Nature of the transaction

Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2022 to 31 March 2022.

 

 

 

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

$42.28

996.330

 

 

 

 

 

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

 

e)

Date of the transaction

2022-03-23

f)

Place of the transaction

 

N/A

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Jesse Goodman

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

 

b)

Nature of the transaction

Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2022 to 31 March 2022.

 

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

$42.28

328.789

 

 

 

 

 

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

 

e)

Date of the transaction

2022-03-23

f)

Place of the transaction

 

N/A

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr Urs Rohner

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2022 to 31 March 2022.

 

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£15.90

530.704

 

 

 

 

 

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

 

e)

Date of the transaction

2022-03-23

f)

Place of the transaction

 

N/A

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHDXLFLLXLBBBF

Companies

GSK (GSK)
UK 100

Latest directors dealings